Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 2 (February)

1. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
   Biochem Pharmacol, 75(4): 836-46. [Abstract] [Full-text]
2. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.
   Future Oncol, 4(1): 125-31. [Abstract] [Full-text]
3. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation.
   Int J Gynecol Cancer. [Abstract] [Full-text]
4. Accessibility to targeted oncology drugs in Slovenia and selected European countries.
   Eur J Cancer, 44(3): 408-18. [Abstract] [Full-text]
5. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.
   Cancer Chemother Pharmacol. [Abstract] [Full-text]
6. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice.
   Pharmacoepidemiol Drug Saf, 17(2): 125-34. [Abstract] [Full-text]
7. Selective probing and imaging of cells with single walled carbon nanotubes as near-infrared fluorescent molecules.
   Nano Lett, 8(2): 586-90. [Abstract] [Full-text]
8. HER-2/neu expression in primary and metastatic breast cancer.
   Breast Cancer Res Treat. [Abstract] [Full-text]
9. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.
   J Cardiovasc Magn Reson, 10(1): 5. [Abstract] [Full-text]
10. Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases.
    Breast, 17(1): 80-4. [Abstract] [Full-text]
11. Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity.
    Clin Cancer Res, 14(4): 1192-9. [Abstract] [Full-text]
12. Solamargine Enhances HER2 Expression and Increases the Susceptibility of Human Lung Cancer H661 and H69 Cells to Trastuzumab and Epirubicin.
    Chem Res Toxicol, 21(2): 393-9. [Abstract] [Full-text]
13. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.
    Am J Clin Pathol, 129(3): 383-90. [Abstract] [Full-text]
14. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
    Ann Oncol, 19(3): 487-95. [Abstract] [Full-text]
15. Two-sided fluorescence resonance energy transfer for assessing molecular interactions of up to three distinct species in confocal microscopy.
    Cytometry A, 73(3): 209-19. [Abstract] [Full-text]
16. Molecular testing for somatic cancer mutations: a survey of current and future testing in UK laboratories.
    J Clin Pathol, 61(3): 373-6. [Abstract] [Full-text]
17. HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review.
    Gynecol Oncol. [Abstract] [Full-text]
18. The medical treatment of inflammatory breast cancer.
    Semin Oncol, 35(1): 64-71. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.